首页> 外文期刊>Medicinal chemistry research: an international journal for rapid communications on design and mechanisms of action of biologically active agents >Synthesis, central nervous system activity, and structure-activity relationship of l-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo [1,2-a]pyrimidine-5(1H)-ones
【24h】

Synthesis, central nervous system activity, and structure-activity relationship of l-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo [1,2-a]pyrimidine-5(1H)-ones

机译:1-芳基-6-苄基-7-羟基-2,3-二氢咪唑并[1,2-a]嘧啶-5(1H)-ones的合成,中枢神经系统活性和构效关系

获取原文
获取原文并翻译 | 示例
           

摘要

A series of 24 1-aryl-6-benzyl-7-hydroxy-2,3-dihydroimidazo[1,2-a]pyrimidine-5(1H)-ones was designed as antinociceptive compounds acting through opioid receptors with additional serotoninergic activity. The compounds, similarly as previously published series, lack the protonable nitrogen atom which is a part of classical opioid receptor pharmacophore and is necessary to interact with the conserved Asp(3.32) in the opioid receptor binding pocket. The compounds were obtained in one-step cyclocondensation of 1-aryl-4,5-dihydro-1H-imidazol-2-amines diethyl 2-benzyl-malonate or diethyl 2-(2-chlorobenzyl)malonate under basic conditions. Almost all the tested compounds exerted strong antinociceptive activity, but surprisingly, it was not reversed by naloxone; thus, it is not mediated through opioid receptors. It makes it possible to conclude that addition of one more aromatic moiety to the non-classical opioid receptor pharmacophore results in the compounds which are not opioid receptor ligands. The lack of activity of one of the tested compounds may be attributed to low blood-brain barrier permeation or unfavorable distribution of electrostatic potential and HOMO and LUMO orbitals.
机译:设计了一系列24个1-芳基-6-苄基-7-羟基-2,3-二氢咪唑并[1,2-a]嘧啶-5(1H)-酮类化合物作为镇痛化合物,通过阿片受体起作用,具有额外的5-羟色胺能活性。该化合物与以前发表的系列类似,缺少质子化的氮原子,这是经典阿片受体药效团的一部分,是与阿片受体结合口袋中保守的Asp(3.32)相互作用所必需的。在碱性条件下,将1-芳基-4,5-二氢-1H-咪唑-2-胺二乙基2-苄基丙二酸酯或二乙基2-(2-氯苄基)丙二酸酯一步缩合得到化合物。几乎所有受测化合物均具有很强的抗伤害感受活性,但令人惊讶的是,纳洛酮并未逆转;因此,它不是通过阿片受体介导的。可以得出这样的结论,即向非经典阿片受体药效基团中添加一个以上的芳族基团会导致该化合物不是阿片受体配体。所测试化合物之一的活性不足可能归因于血脑屏障渗透性低或静电势以及HOMO和LUMO轨道的不利分布。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号